ValiRx PLC Notice of AGM (3902E)

TIDMVAL

RNS Number : 3902E

ValiRx PLC

05 May 2017

ValiRx Plc

("ValiRx" or the "Company")

Posting of Annual Report and Accounts

&

Notice of Annual General Meeting

London, UK, 5 May 2017: ValiRx Plc (AIM: VAL) is a life science company with a focus on cancer therapeutics and diagnostics for personalised medicine.

The Company announces that its Annual Report and Accounts for the year ended 31 December 2016 has been published, is available on the Company's website, www.valirx.com and has been posted to registered shareholders today.

The Company also advises that the Notice of its Annual General Meeting ("AGM"), its Chairman's Letter to Shareholders and the Form of Proxy for the AGM are now available on its website, www.valirx.com and these have also been posted to registered shareholders.

The Company's AGM will be held on 30 May 2017 at 10.00am at the offices of DAC Beachcroft LLP, 100 Fetter Lane, London, EC4A 1BN.

*** ENDS ***

For more information, please contact:

 
 ValiRx plc                                 Tel: +44 (0) 20 
                                             3008 4416 
                                             www.valirx.com 
 Dr Satu Vainikka, Chief Executive          Tel: +44 (0) 20 
                                             3008 4416 
 Tarquin Edwards, Head of Communications.   Tel: [phone] 
                                             458 364 
                                             [e-mail] 
 Cairn Financial Advisers LLP               Tel: +44 (0) 20 
  (Nominated Adviser)                        7213 0880 
  Richard Nash/Liam Murray 
 Beaufort Securities Limited                Tel: +44 (0) 207 
  (Broker)                                   382 8300 
  Jon Belliss 
 

Notes for Editors

ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in "precision" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.

The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field.

ValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights. They originate or derive from Word class institutions, such as Cancer Research UK and Imperial College.

Until recently, cancer treatments relied on non-specific agents, such as chemotherapy. With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients.

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NOASSLFMIFWSEEI

(END) Dow Jones Newswires

May 05, 2017 12:28 ET (16:28 GMT)